A global healthcare supplier. The company develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients (API). It is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market.
Perrigo Israel was founded under the name Agis and in 2004, Agis was purchased by Perrigo US and became its fully-owned subsidiary. Perrigo Israel imports, manufactures and distributes RX products, OTC medications, diagnostics and medical devices, and has 900 employees. Perrigo is the second largest pharmaceutical company on the Israeli market by sales volume.
As a dominant part of the Israeli pharmaceutical industry, Perrigo enjoys the advantages generated by the Israeli occupation of Palestinian lands allowing the company to exploit the Palestinian market. ‘Quality and Security reasons’ in conjunction with economic and political justifications create a Palestinian captive market for Israeli and multinational companies.
The Paris Protocol, an annex to the Oslo Accords, which regulates the financial relations between Israel and the future Palestinian state, placed both entities under the same taxation envelope. As a result, the Palestinians continue to depend on Israeli policies, customs laws and services for the import and export of goods. This dependency has inflicted strong negative economic effects on the Palestinian pharmaceutical industry. Various hindrances generate extra costs that harm the development of the local industry: the burden of the annual licensing of imported raw materials, the costs of back-to-back deliveries to and from the WB and the GS, the costs of shipping drugs in bulk via Jordan, the exclusion of large Arab markets as well as in Israel, and the inability of the Gazan industry to develop and expand due to the prohibition on export.
Perrigo, likewise other Israeli and multinational companies, enjoys the aforementioned situation in several ways. The company enjoys easy access to the Palestinian market, free of customs and checkpoint, e.g. change of trucks at cargo checkpoints. Perrigo’s agents do not have to amend any of their products in order to sell them in the OPT. Thus, the company can sell drugs that are not labeled in Arabic. Perrigo meets little to no competition from the cheaper generic drug industry, as a result of the Israeli Ministry of Health restrictions on drug registration in Israel and their enforcement on the Palestinian market.
Major shareholders: Fidelity Management & Research Company (8.37%), Perrigo Company (8.23%) BlackRock (6.69%) and Moshe Arkin (5.34%).
Through its fully owned subsidiaries, Perrigo engages in the production and distribution of consumer healthcare products, generic prescription drugs, API and consumer products, primarily in the United States, Australia, Israel, Europe, India and Mexico.
Main Subsidiaries (partial list):
US – L. Perrigo Company | Perrigo Company of South Carolina | Perrigo New York | Perrigo Holland (formerly J.B. Laboratories) | Perrigo Florida (formerly Unico Holdings)
Israel – Perrigo Israel Pharmaceuticals
UK – Wrafton Laboratories | Brunel Pharma (formerly Brunel Healthcare) | Galpharm Healthcare
Mexico – Quimica y Farmacia, SA de CV | Laboratorios Diba, S.A
Germany – Chemagis
China – Zibo Xinhua – Perrigo Pharmaceutical Company
India – Perrigo Laboratories India Pvt
Australia – Orion Laboratories Pty
The company collaborates with numerous international pharmaceutical and diagnostic companies, e.g.: Solvay, Nycomed, Talecris, Schwarz Pharma, Siemens Healthcare Diagnostics, GSK, Genzyme, Allergan and Sakura.
All the information contained in this page is valid until Sun 22/07/2012